Skip to main content

Table 1 Baseline and clinical characteristics of HC and PD participants

From: Parkinson's disease peripheral immune biomarker profile: a multicentre, cross-sectional and longitudinal study

Characteristics Discovery cohort Validation cohort Pa Pb
PDa (N = 76) HCb (N = 76) p PDa (N = 80) HCb (N = 80) p
Age (years) 62.2 ± 7.5 60.2 ± 8.2 0.14 63.7 ± 8.5 64.9 ± 8.8 0.40 0.25 0.01
Sex, N         
 Female 38 28 0.14 44 39 0.43 0.63 0.15
 Male 38 48   36 41    
Disease duration (years) 4.9 ± 4.3 /   3.6 ± 3.6 /    
UPDRS I 8.0 ± 6.1 / / 6.2 ± 4.5 / / 0.05 /
UPDRS II 11.5 ± 6.8 / / 12.7 ± 6.9 / / 0.28 /
UPDRS III 28.4 ± 15.1 / / 35.4 ± 18 / / 0.01 /
  1. Data are expressed as mean and standard deviation (SD), as appropriate
  2. Pa: comparation of PD participants between discovery and validation cohort; Pb: comparation of HC participants between discovery and validation cohort
  3. PD Parkinson’s disease, UPDRS Unified Parkinson's Disease Rating Scale